Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Ro and Brello represent two distinct telehealth models for GLP-1 access. Ro operates a direct-to-consumer platform with semaglutide (compounded) and tirzepatide, while Brello connects patients with independent licensed prescribers. Both address the growing demand for weight management and metabolic support, yet serve different patient preferences and clinical workflows.
Patients evaluating these platforms face critical decisions about provider interaction, medication formulation, genetic screening, and cost structure. The choice between Ro's standardized approach and Brello's prescriber-focused model impacts treatment personalization and long-term outcomes. PlexusDx emphasizes precision wellness by offering genetic insights and compounded medications from licensed 503A pharmacies to support informed medical conversations with qualified providers.
Ro: Platform Structure and GLP-1 Offerings
Ro operates as a vertically integrated telehealth company with in-house clinicians and a direct medication fulfillment model. Patients interact with Ro's employed medical team, receive compounded semaglutide or tirzepatide, and have prescriptions filled through Ro's pharmacy partners. This model emphasizes convenience and consistent clinical protocols.
Ro's GLP-1 pricing typically ranges from $199 to $399 monthly, depending on medication and dosage. The platform provides telehealth consultations, ongoing monitoring, and dose adjustments. However, patients work exclusively within Ro's clinical ecosystem, limiting flexibility to switch providers or pursue alternative compounding sources while remaining enrolled.
Brello: Independent Prescriber Network Model
Brello functions as a marketplace connecting patients with independent licensed prescribers—physicians, nurse practitioners, and physician assistants—who specialize in GLP-1 management. Rather than employing clinicians, Brello facilitates the relationship between patient and prescriber, offering flexibility and personalized care pathways.
Brello's pricing depends on the individual prescriber's fees, typically ranging from $150 to $350 monthly plus medication costs. Patients maintain an ongoing relationship with their chosen provider, who retains clinical autonomy. This model appeals to those seeking continuity of care with a specific clinician rather than platform-mediated protocols.
Platform Comparison: Key Differences and Clinical Implications
Ro and Brello differ fundamentally in operational structure, provider relationship, clinical customization, and medication sourcing. Understanding these distinctions helps patients select a platform aligned with their medical history, treatment goals, and preference for clinical autonomy versus standardized protocols.
| Factor |
Ro |
Brello |
| Provider Model |
Employed Ro clinicians; standardized protocols |
Independent licensed prescribers; variable approaches |
| Medication Options |
Compounded semaglutide, tirzepatide; Ro-partner pharmacies |
Determined by prescriber; may include branded or compounded |
| Monthly Cost Range |
$199–$399 (medication + consultation) |
$150–$350 (prescriber fees) plus pharmacy charges |
| Continuity of Care |
Consistent Ro clinician team; possible reassignments |
Single prescriber; ongoing relationship maintained |
| Genetic Testing Integration |
Not standard offering; case-by-case basis |
Varies by prescriber; limited standardization |
| Medication Flexibility |
Limited to Ro formulations and partners |
Provider-dependent; may access varied compounders |
Clinical Evaluation: Who Benefits From Each Model
Ro suits patients seeking a streamlined, standardized telehealth experience with consistent protocols, transparent pricing, and minimal decision-making friction. Individuals new to GLP-1 therapy or those who value simplicity often find Ro's model efficient and supportive of early treatment phases.
Brello appeals to patients with complex medical histories, prior telehealth experience, or strong preferences for continuity with a specific clinician. Those seeking nuanced, multi-visit relationships and higher degrees of clinical customization may benefit from Brello's prescriber-focused approach. Patients with contraindications or comorbidities requiring detailed specialist input often prefer independent prescriber models.
Safety, Screening, and Ongoing Monitoring Protocols
Both Ro and Brello conduct baseline health screening before dispensing GLP-1 medications. Ro performs standardized intake assessments; Brello protocols vary by prescriber. Each model should assess cardiovascular history, thyroid risk, pancreatic health, and contraindications. Ongoing monitoring—vital signs, medication tolerance, dose adjustments—differs by platform and prescriber.
Neither platform currently integrates genetic peptide pathway testing as a standard offering, though some Brello prescribers may offer adjunct assessments. Patients should ask each platform about baseline labs, follow-up frequency, and adverse event protocols. Safety depends on honest symptom reporting and regular provider contact, not platform type alone.
Genetic Insights and Precision Wellness Integration
Ro and Brello do not routinely incorporate genetic testing into GLP-1 selection, leaving a gap in precision-wellness methodology. Genetic predispositions in peptide pathways—GLP1R, GIPR, FTO, MC4R variants—may help provide context for individual medication response variability, yet most telehealth platforms rely on empirical dose escalation and symptom tracking.
PlexusDx offers the Precision Peptide Genetic Test, available as a $99 add-on or $298 standalone, which reveals predispositions in peptide genetic pathways. This test may help support a more personalized conversation between patient and provider about GLP-1 or alternative compounded peptide protocols. Importantly, genetic predisposition does not predict exact medication response; it should be interpreted alongside clinical assessment and provider judgment.
Patients considering either Ro or Brello may benefit from discussing genetic wellness integration with their prescriber. A qualified healthcare provider can evaluate genetic insights alongside medical history, BMI, metabolic markers, and tolerance data to refine treatment selection and dosing strategies. Precision wellness complements, rather than replaces, rigorous clinical evaluation.
How PlexusDx Supports a More Personalized Approach
Both Ro and Brello provide valuable telehealth pathways to GLP-1 access, yet neither integrates genetic peptide pathway testing into standard workflows. PlexusDx emphasizes that genetic predispositions in GLP1R, GIPR, FTO, and MC4R variants may help contextualize individual response patterns, supporting more informed medical conversations without guaranteeing specific outcomes.
The Precision Peptide Genetic Test through PlexusDx can be added to any medical evaluation ($99 add-on) or ordered standalone ($298). This test reveals predispositions in peptide genetic pathways—distinct from pharmacogenomic testing—and may help providers and patients explore whether compounded GLP-1 medications or alternative peptide protocols align with individual genetic profiles. Results should always be discussed with a qualified healthcare provider.
PlexusDx compounded medications—semaglutide from $149/mo, tirzepatide from $249/mo—come from licensed 503A pharmacies and may serve as complements to telehealth provider relationships. Whether you choose Ro, Brello, or another platform, discussing genetic insights and compounding options with your prescriber can support a more comprehensive, personalized treatment plan.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main difference between Ro and Brello for GLP-1 treatment?
Ro employs in-house clinicians and manages medication fulfillment directly; Brello connects you with independent prescribers who retain clinical autonomy. Ro offers standardized protocols; Brello prioritizes prescriber-patient continuity and customization.
Is Ro or Brello more affordable?
Ro typically costs $199–$399 monthly all-inclusive. Brello ranges $150–$350 for prescriber fees plus separate pharmacy costs, making final pricing variable. Compare your specific prescriber and medication choices directly.
Do Ro and Brello offer genetic testing for GLP-1 response?
Neither platform includes genetic peptide pathway testing as standard. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on, $298 standalone) to reveal predispositions in GLP1R, GIPR, FTO, and MC4R variants, supporting personalized provider conversations.
Can I use compounded GLP-1 medications with Ro or Brello?
Ro dispenses its own compounded semaglutide and tirzepatide. Brello prescribers may recommend various sources. PlexusDx compounded medications from 503A pharmacies work alongside any telehealth provider relationship with prescriber approval.
Which platform is better for patients with complex medical histories?
Brello's independent prescriber model often suits complex cases requiring specialist oversight and ongoing customization. Ro's standardized protocols work well for straightforward presentations. Your medical history should guide platform selection in consultation with a provider.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Mochi vs Medvi: Genetic Testing and GLP-1 Personalization
Mochi vs Hims: Genetic Testing for Personalized GLP-1 Selection